购物车
- 全部删除
- 您的购物车当前为空
Tislelizumab (BGB-A317) 是一种靶向人程序性死亡受体-1(PD-1)IgG4类单克隆抗体,具有抗肿瘤活性,抑制 Fcγ 受体与巨噬细胞的结合,可用于研究晚期鳞状非小细胞肺癌。
为众多的药物研发团队赋能,
让新药发现更简单!
Tislelizumab (BGB-A317) 是一种靶向人程序性死亡受体-1(PD-1)IgG4类单克隆抗体,具有抗肿瘤活性,抑制 Fcγ 受体与巨噬细胞的结合,可用于研究晚期鳞状非小细胞肺癌。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 993 | 现货 | |
5 mg | ¥ 2,880 | 现货 | |
10 mg | ¥ 4,560 | 现货 | |
25 mg | ¥ 6,900 | 现货 | |
50 mg | ¥ 9,490 | 现货 | |
100 mg | ¥ 12,800 | 现货 |
产品描述 | Tislelizumab (BGB-A317) is an IgG4 class monoclonal antibody targeting human programmed death receptor-1 (PD-1) with antitumor activity that inhibits the binding of Fcγ receptor to macrophages and can be used to study advanced squamous non-small cell lung cancer. |
别名 | 替雷利珠单抗, VDT-482, BGB-A317 |
CAS No. | 1858168-59-8 |
存储 | store at low temperature | store at -20°C | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容